BioNTech SE Sponsored ADR BNTX
98.52
(0.74)
(0.75%)
as of 25 Sep
- Market cap
- $24.9B
- P/E
- 0.0×
Follow BNTX
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(2.99%) | (6.01%) | (7.03%) | (9.53%) | |
| (2.57%) | (5.22%) | (6.26%) | (8.24%) | ||
ROIC |
(13.11%) | (19.03%) | (22.28%) | (38.39%) | |
Return on Tangible Assets |
(3.72%) | (7.53%) | (8.44%) | (11.87%) | |
Average Days of Receivables |
93.74 | 124.23 | 80.73 | 33.00 | |
Free Cash Flow per Share |
(5.15) | (1.35) | 2.22 | 1.98 | |
Free Cash Flow |
(1,231.70) | (326.41) | 563.49 | 500.72 | |
Capital Expenditures |
(889.87) | (842.33) | (282.16) | (257.85) | |
Piotroski F-Score |
2.00 | 4.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(0.88%) | 1.33% | 2.15% | 1.99% | |
Accounts Receivable Turnover |
3.17 | 2.37 | 3.59 | 3.17 | |
Accounts Payable Turnover |
0.93 | 1.36 | 1.42 | 1.13 | |
Inventory Turnover |
2.04 | 3.36 | 3.70 | 3.95 | |
Average Days of Payables |
280.17 | 304.20 | 277.61 | 367.17 | |
Days of Inventory on Hand |
158.17 | 62.96 | 61.47 | 57.12 | |
Tax Rate |
0.10 | 0.08 | 0.06 | 0.03 | |
Research and Development Expense of Revenue |
69.28% | 73.34% | 77.67% | 84.20% | |
Selling, General and Administrative Expense of Revenue |
16.92% | 21.76% | 23.68% | 27.49% | |
Share Based Compensation of Revenue |
2.50% | 2.82% | 3.02% | 2.66% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.54 | (0.40) | (0.58) | (0.38) | |
Depreciation/Fixed assets |
0.36 | 0.35 | 0.41 | 0.65 | |
Capex/Depreciation |
(2.06) | (1.94) | (0.53) | (0.33) | |
Revenue per Share |
14.76 | 13.43 | 12.61 | 11.92 | |
Operating CF per Share |
(1.43) | 2.13 | 3.34 | 2.99 | |
Capex per Share |
(3.72) | (3.48) | (1.11) | (1.02) | |
Capex to Sales |
0.25 | 0.26 | 0.09 | 0.09 | |
Net Profit Margin |
(18.02%) | (39.59%) | (46.04%) | (65.75%) |
Columns are period end dates